A PHASE-I, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE TOLERANCE AND PHARMACOKINETIC BEHAVIOR OF RP 59500

被引:48
作者
ETIENNE, SD [1 ]
MONTAY, G [1 ]
LELIBOUX, A [1 ]
FRYDMAN, A [1 ]
GARAUD, JJ [1 ]
机构
[1] RHONE POULENC RORER RECH & DEV,INST BIOPHARM,F-92160 ANTONY,FRANCE
关键词
D O I
10.1093/jac/30.suppl_A.123
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The tolerance and pharmacokinetic behaviour of a new injectable streptogramin antibiotic, RP 59500 were evaluated on 26 healthy male volunteers in a double-blind, placebo-controlled, phase I study. The doses used were 1.4, 2.8, 4.6, 7.0, 9.8, 12.6, 16.8, 22.4 and 29.4 mg/kg; each dose was administered as a 1 h infusion to eight subjects, two of them receiving placebo. Blood levels of RP 59500 were measured by both microbiological and HPLC assays. At the end of the infusion, C for RP 59500 ranged from 0.95 ± 0.22 to 24.20 ± 8.82 mg/L. The apparent elimination half-life of the compound ranged from 1.27 to 1.53 h. RP 59500 did not significantly affect any of the laboratory or clinical assessments (blood pressure, pulse rate, ECG, peak expiratory flow rate). Reported adverse effects were of mild intensity; the most frequent event was mild pain or burning at the infusion site with doses of 7 mg/kg or higher. These results support further studies of RP 59500 in phase II clinical trials. © 1992 Oxford University Press.
引用
收藏
页码:123 / 131
页数:9
相关论文
共 9 条
[1]   VANCOMYCIN AND RED NECKS [J].
ACKERMAN, BH ;
BRADSHER, RW .
ANNALS OF INTERNAL MEDICINE, 1985, 102 (05) :723-724
[2]   PHARMACOKINETICS AND SERUM BACTERICIDAL ACTIVITY OF VANCOMYCIN ALONE AND IN COMBINATION WITH CEFTAZIDIME IN HEALTHY-VOLUNTEERS [J].
BOECKH, M ;
LODE, H ;
BORNER, K ;
HOFFKEN, G ;
WAGNER, J ;
KOEPPE, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (01) :92-95
[3]   INVITRO AND INVIVO SYNERGIC ACTIVITY AND FRACTIONAL INHIBITORY CONCENTRATION (FIC) OF THE COMPONENTS OF A SEMISYNTHETIC STREPTOGRAMIN, RP 59500 [J].
BOUANCHAUD, DH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 :95-99
[4]   RETROSPECTIVE STUDY OF THE TOXICITY OF PREPARATIONS OF VANCOMYCIN FROM 1974 TO 1981 [J].
FARBER, BF ;
MOELLERING, RC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 23 (01) :138-141
[5]   PERCENTAGES AND DISTRIBUTIONS OF TEICOPLANIN-RESISTANT AND VANCOMYCIN-RESISTANT STRAINS AMONG COAGULASE-NEGATIVE STAPHYLOCOCCI [J].
GOLDSTEIN, FW ;
COUTROT, A ;
SIEFFER, A ;
ACAR, JF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (05) :899-900
[6]  
MAILLARD MA, 1965, ANN I PASTEUR PARIS, V109, P314
[7]   INVITRO ACTIVITIES OF VANCOMYCIN AND TEICOPLANIN AGAINST COAGULASE-NEGATIVE STAPHYLOCOCCI ISOLATED FROM NEUTROPENIC PATIENTS [J].
MAUGEIN, J ;
PELLEGRIN, JL ;
BROSSARD, G ;
FOURCHE, J ;
LENG, B ;
REIFFERS, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (05) :901-903
[8]   POSTANTIBIOTIC EFFECTS OF RP 59500 WITH STAPHYLOCOCCUS-AUREUS [J].
NOUGAYREDE, A ;
BERTHAUD, N ;
BOUANCHAUD, DH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 :101-106
[9]   STAPHYLOCOCCUS-EPIDERMIDIS - AN INCREASING CAUSE OF INFECTION IN PATIENTS WITH GRANULOCYTOPENIA [J].
WADE, JC ;
SCHIMPFF, SC ;
NEWMAN, KA ;
WIERNIK, PH .
ANNALS OF INTERNAL MEDICINE, 1982, 97 (04) :503-508